Navigation Links
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
Date:11/7/2007

unction," said Atul Deodhar, MD, associate professor of medicine, Oregon Health and Science University, Portland, Oregon. "These findings show that golimumab improved both the signs and symptoms of ankylosing spondylitis and patients' physical function, which is promising in the treatment of this systemic inflammatory disease."

Findings from the GO-RAISE study showed that golimumab-treated patients experienced significant functional improvements as measured by the BASFI, a 1 to 10 scale (1 representing no impairment and 10 representing severe impairment), which measures physical function and impairment due to the disease and subsequent improvements as a result of treatment. Patients receiving golimumab 50 mg and 100 mg experienced an average decrease of 1.4 and 1.5 units from baseline in BASFI score, respectively, at week 14, compared with an average increase of 0.1 units among patient receiving placebo (P < 0.001 for both comparisons).

"We are encouraged by the findings from this Phase 3 trial evaluating golimumab as a treatment for ankylosing spondylitis," said Jerome A. Boscia, MD, senior vice president, Clinical Research and Development, Centocor, Inc. "These data suggest golimumab may be an effective treatment option for patients with this chronic, progressive spondyloarthropathy."

About the GO-RAISE Trial

The GO-RAISE trial included 356 patients with active ankylosing spondylitis. Subjects were randomized to receive subcutaneous injections of golimumab 50 mg or 100 mg or placebo every four weeks. The primary endpoint was the proportion of patients achieving ASAS 20 at week 14. At week 16, patients in the placebo or 50 mg group demonstrating less than 20 percent improvement from baseline in both total back pain and morning stiffness measures were switched to either golimumab 50 mg (previously receiving placebo) or golimumab 100 mg (previously receiving golimumab 50 mg).

Through week 24, golimumab was generally well tolerated with f
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Multiple Sclerosis Drugs Market 2014-2018" report to their ... inflammatory medical condition that results in demyelination, axonal transection, ... an abnormal response by the immune system, which targets ... a potentially debilitating disease in which the damage of ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in ... Avimex distributes biological and pharmaceutical products for use in ... world. Avimex is providing financial support for the ...
... , SHENYANG, China, Oct. 20 ... "Company"), a leading China-based biotechnology,company focused on researching, developing, ... its annual general,meeting of shareholders held on October 12, ... the Company,s shareholders re-elected Dr. Jing Lou and Mr.,Moujia ...
Cached Medicine Technology:Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 2Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 3Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 4Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5
(Date:8/30/2014)... Patients suffering from vitiligo can now ... new review published by Daily Gossip. , Vitiligo ... there is no wonder that numerous sufferers search for ... Treatment is one of the most appreciated such methods ... to stop the spread of this disorder immediately, while ...
(Date:8/30/2014)... Daily Gossip magazine reveals in its ... panic attacks under control with a simple and efficient ... describes this new method as an anxiety recovery program ... overcome general anxiety related disorders. , What makes ... that it can be accessed by users from the ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 The ... facilities in New Jersey and even in the U.S. ... that takes inches off of patients’ waists with deep-tissue ... cells in small sections, Vanquish is more inclusive to ... Patients lay comfortably under panels about one inch ...
(Date:8/30/2014)... 2014 RB SEO Services, a well-recognized ... for small businesses. , RBSEO Services knows this very ... search engine optimization service. So, the company has introduced ... account. , On being asked about the service, ... low cost SEO service because many small businesses expressed ...
(Date:8/30/2014)... NY (PRWEB) August 30, 2014 ... throughout the planet has been one of the ... order to create a positive impact around the ... and staffed with top trained executives and trainers ... of people worldwide. Vital statistics demonstrate that ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2
... , , , FOSTER ... WHAT: Siperian, Inc., a leading industry provider of a multidomain master ... IBM Global Business Services and Boehringer Ingelheim have teamed up for an ... Most Valuable?" Hussain Mooraj, vice president, Healthcare ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- At ... September 10, reporters were informed that the,First World Conference ... Physicians) and the First World Endoscopy Technology Expo,will be ... Professor Zhang Yangde, the chief ...
... HBV genotypes as well as mutations in the core promoter, ... association with the clinical outcome of liver disease, however, this ... the HBV genotype distribution in certain region. So far, there ... country with a big population and a relatively high HBV ...
... , , MENLO PARK, ... label-free technology that accelerates the development of biotherapeutic and pharmaceutical ... and Read Immunogenicity Assay Kit for rapid detection of anti-drug ... new assay kit provides life science researchers with new levels ...
... , , , NEW YORK, ... has received Orphan-Drug designation from the U.S. Food and Drug Administration ... announced that it had reached an agreement with the FDA regarding ... 3 trial in relapsed/refractory multiple myeloma and that the study is ...
... study finds supervised exercise has better results , WEDNESDAY, ... than shockwave treatment for relieving chronic shoulder pain, according ... used to treat shoulder pain, even though a number ... investigate, Norwegian researchers studied 104 men and women, aged ...
Cached Medicine News:Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 2Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 3Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 4Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 5Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3Health News:ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 3Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 4Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2
Stainless steel tray for sterilizing instruments....
For sterilizing, carrying and storage of a Storz diamond knife and barrel gauge....
Diamond knife tray with silicone inserts to securely hold the diamond knife....
Diamond knife tray with silicone inserts to securely hold the diamond knife....
Medicine Products: